Page last updated: 2024-12-06

dibenzo-18-crown-6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibenzo-18-crown-6 (DB18C6) is a macrocyclic polyether that is commonly used as a selective host for alkali metal cations, particularly potassium ions. It is synthesized through a multi-step process involving the reaction of catechol with a suitable dihaloalkane, typically 1,2-dibromoethane. The crown ether structure of DB18C6 allows it to encapsulate potassium ions through electrostatic interactions and hydrogen bonding with the ether oxygens. This complexation ability has led to numerous applications, including:

* **Phase-transfer catalysis:** DB18C6 facilitates the transfer of potassium salts from an aqueous phase to an organic phase, enabling reactions that would otherwise be difficult.
* **Sensors:** The complexation of potassium ions by DB18C6 can be used to develop sensors for the detection of potassium in various applications, such as environmental monitoring and medical diagnostics.
* **Separation science:** DB18C6 is employed in chromatographic separations to isolate and purify potassium-containing compounds.
* **Ionophores in membrane transport:** DB18C6 serves as an ionophore to facilitate the transport of potassium ions across cell membranes, influencing membrane permeability and ionic gradients.

The selectivity of DB18C6 for potassium ions makes it a valuable tool for understanding and manipulating biological processes. Its complexation properties are also being explored for various technological advancements, including the development of new materials, catalysts, and sensors.'
```

dibenzo-18-crown-6: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dibenzo-18-crown-6 : A crown ether that is 18-crown-6 ortho-fused to two benzene rings at positions 8-9 and 17-18. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID26541
CHEMBL ID345536
CHEBI ID358732
SCHEMBL ID35765
MeSH IDM0043219

Synonyms (63)

Synonym
BIDD:ER0368
AE-641/00796004
6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecine
dibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecane
dibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin, 6,7,9,10,17,18,20,21-octahydro-
6,7,9,10,17,18,20,21-octahydrodibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin
einecs 238-041-3
brn 1162153
2,3:11,12-dibenzo-1,4,7,10,13,16-hexaoxacyclooctadecane
dibenzo(a,j)-1,4,7,10,13,16-hexaoxacyclooctadeca-2,11-diene
nsc 147771
dibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin, 6,7,9,10,17,18,20,21-octahydro-
STK365301
dibenzocrown
dibenzo[b,4,7,10,13,16]hexaoxacyclooctadecane
crown-18
dibenzo-18-crown-6
dibenzo[b,4,7,10,13,16]hexaoxacyclooctadecin, 6,7,9,10,17,18,20,21-octahydro-
nsc-147771
dibenzo-18-crown-6-ether
nsc147771
crown 18
14187-32-7
dibenzo-18-crown-6, 98%
CHEBI:358732 ,
dibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecane
CHEMBL345536
AKOS001483343
dibenzo-18-crown 6-ether
D1533
BBL000666
6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin
unii-0a7w45jcs9
0a7w45jcs9 ,
6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecene
2,3,11,12-dibenzo-1,4,7,10,13,16-hexaoxacyclooctadeca-2,11-diene
FT-0624631
6,7,9,10,17,18,20,21-octahydrodibenzo[b,k]-[1,4,7,10,13,16]hexaoxacyclooctadecine
SCHEMBL35765
SY011465
mfcd00005098
6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclo-octadecin
dibenzo 18-crown-6
2,3,11,12 -dibenzo-1,4,7,10,13,16-hexaoxacyclooctadeca-2,11-diene
dibenzo-18-crown
dibenzo-18-crown-6 ether
crown ether dibenzo-18-crown-6
1,4,7,14,17,20-hexaoxa-[7.7]orthocyclophane
DTXSID6022428
J-520232
tin(ii) ionophore i, selectophore(tm)
J-007564
F0001-0493
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0,(1)]hexacosa-1(22),9(14),10,12,23,25-hexaene
BCP24528
Q5272256
AS-12065
CS-0002003
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.09,14]hexacosa-1(26),9,11,13,22,24-hexaene
2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0,9,14]hexacosa-1(22),9(14),10,12,23,25-hexaene
EN300-37135
Z381040662
HY-40309
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
phase-transfer catalystA catalyst that facilitates the migration of a reactant from one phase into another phase where reaction occurs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
crown etherCrown compounds containing only oxygen as coordinating atom.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID280248Antiproliferative activity against SW620 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID50775In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Anticoccidial activity of crown polyethers.
AID280247Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID611984Antibacterial activity against Escherichia coli assessed as growth inhibition at 10'-4 M after 105 mins2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
AID280246Antiproliferative activity against HeLa cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID611986Antibacterial activity against Bacillus subtilis after 70 mins2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns.
AID280245Antiproliferative activity against H460 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID280249Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (21.88)18.7374
1990's0 (0.00)18.2507
2000's8 (25.00)29.6817
2010's17 (53.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.47 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index47.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]